GERON CORP Assets, Fair Value Adjustment
GERON CORP (GERN) reported Assets, Fair Value Adjustment of -$163.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-16.
Discontinued › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueAdjustment · last filed 2023-03-16
- GERON CORP assets, fair value adjustment for the quarter ending 2020-12-31 was $24.00K.
- GERON CORP assets, fair value adjustment for the quarter ending 2020-09-30 was $92.00K, a 55.98% decline year-over-year.
- GERON CORP assets, fair value adjustment for the quarter ending 2020-06-30 was -$499.00K, a 570.75% decline year-over-year.
- GERON CORP assets, fair value adjustment for the quarter ending 2020-03-31 was $220.00K.
- GERON CORP assets, fair value adjustment for fiscal 2020 was -$163.00K, a 183.16% decline from fiscal 2019.
- GERON CORP assets, fair value adjustment for fiscal 2019 was $196.00K, a 67.55% decline from fiscal 2018.
- GERON CORP assets, fair value adjustment for fiscal 2018 was $604.00K.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $116.00K derived: sum of 2 quarters · filed 2023-03-16 | -$383.00K derived: sum of 3 quarters · filed 2023-03-16 | -$163.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$407.00K derived: sum of 2 quarters · filed 2021-11-09 | -$187.00K 10-Q · filed 2021-11-09 | -$203.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | -$499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$279.00K 10-Q · filed 2021-08-16 | -$295.00K derived: sum of 3 quarters · filed 2022-03-10 | -$86.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $220.00K 10-Q · filed 2021-05-10 | $204.00K derived: sum of 2 quarters · filed 2022-03-10 | $413.00K derived: sum of 3 quarters · filed 2022-03-10 | $519.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $193.00K derived: sum of 2 quarters · filed 2022-03-10 | $299.00K derived: sum of 3 quarters · filed 2022-03-10 | $196.00K 10-K · filed 2022-03-10 |
| 2019-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $315.00K derived: sum of 2 quarters · filed 2020-11-05 | $212.00K 10-Q · filed 2020-11-05 | $478.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.00K 10-Q · filed 2020-08-06 | $269.00K derived: sum of 3 quarters · filed 2021-03-11 | $94.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$103.00K 10-Q · filed 2020-05-28 | $163.00K derived: sum of 2 quarters · filed 2021-03-11 | -$12.00K derived: sum of 3 quarters · filed 2021-03-11 | $376.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $91.00K derived: sum of 2 quarters · filed 2021-03-11 | $479.00K derived: sum of 3 quarters · filed 2021-03-11 | $604.00K 10-K · filed 2021-03-11 |
| 2018-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $213.00K derived: sum of 2 quarters · filed 2019-11-06 | $338.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $388.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $513.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $125.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |